Conbriza (bazedoxifene)
- Region
- 🇪🇺 EU
- Active substance
- bazedoxifene
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Osteoporosis, Postmenopausal
- CHMP opinion
- Thu 19 Feb 2009
- EU approval
- Fri 17 Apr 2009
- Application
- EMEA/H/C/000913
- ATC
- G03XC02
- Official record
- www.ema.europa.eu
Indication
Conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established. When determining the choice of Conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Duavive Authorised · Pfizer Europe MA EEIG
- 🇪🇺 Brilence Application withdrawn · Wyeth Europa Ltd
Follow Conbriza
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.